• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

IGEM Therapeutics awarded Best Start-up Biotech Company at the UK's OBN Awards


IGEM Therapeutics (London, UK), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, has won the “Best Start-up Biotech Company” award at the OBN Awards 2018.    The award recognizes IGEM as a UK registered start-up biotech company making a significant impact in the sector through news flow, successful fundraising and execution of a robust business plan. The ceremony on Thursday October 11 marked the 10th anniversary of the OBN Awards, which celebrate success stories from the UK life sciences industry over the past year.    Dr. Tim Wilson, Chief Executive Officer of IGEM, commented: “We are thrilled that IGEM Therapeutics has been awarded “Best Start-up Biotech Company” at this year’s prestigious OBN Awards. The award recognizes our efforts to treat cancer by developing novel immunoglobin E antibodies and our significant progress as a company over the last year.” 

Related Videos
Related Content